(E)-3-(benzofuran-5-yl)-1-(5-hydroxy-2-methyl-2-(4-methylpent-3-enyl)-2H-chromen-6-yl)prop-2-en-1-one | 1588827-71-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-3-(benzofuran-5-yl)-1-(5-hydroxy-2-methyl-2-(4-methylpent-3-enyl)-2H-chromen-6-yl)prop-2-en-1-one
• 英文别名: (E)-3-(1-benzofuran-5-yl)-1-[5-hydroxy-2-methyl-2-(4-methylpent-3-enyl)chromen-6-yl]prop-2-en-1-one
• CAS: 1588827-71-7
• 化学式: C₂₇H₂₆O₄
• 分子量: 414.501
• InChiKey: KVFZMPJQLWNQRY-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  59.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1,1-二甲氧基-3,7-二甲基-2,6-辛二烯 在 吡啶 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 (E)-3-(benzofuran-5-yl)-1-(5-hydroxy-2-methyl-2-(4-methylpent-3-enyl)-2H-chromen-6-yl)prop-2-en-1-one
  参考文献：
  名称：

  Design, synthesis, and evaluation of benzofuran-based chromenochalcones for antihyperglycemic and antidyslipidemic activities

  摘要：

  合成了新型双效苯并呋喃类铬喹酮，并对其体内外抗高血糖和抗血脂活性进行了评估。

  DOI：

  10.1039/d2md00341d

文献信息

• Synthesis, Structure–Activity Relationships, and Biological Studies of Chromenochalcones as Potential Antileishmanial Agents
  作者：Rahul Shivahare、Venkateswarlu Korthikunta、Hardik Chandasana、Manish K. Suthar、Pragati Agnihotri、Preeti Vishwakarma、Telaprolu K. Chaitanya、Papireddy Kancharla、Tanvir Khaliq、Shweta Gupta、Rabi Sankar Bhatta、J. Venkatesh Pratap、Jitendra K. Saxena、Suman Gupta、Narender Tadigoppula

  DOI：10.1021/jm401893j

  日期：2014.4.24

  Antileishmanial activities of a library of synthetic chalcone analogues have been examined. Among them, five compounds (11, 14, 16, 17, 22, and 24) exhibited better activity than the marketed drug miltefosine in in vitro studies against the intracellular amastigotes form of Leishmania donovani. Three promising compounds, 16, 17, and 22, were tested in a L. donovani/hamster model. Oral administration of chalcone 16, at a concentration of 100 mg/kg of body weight per day for 5 consecutive days, resulted in >84% parasite inhibition at day 7 post-treatment and it retained the activity until day 28. The molecular and immunological studies revealed that compound 16 has a dual nature to act as a direct parasite killing agent and as a host immunostimulant. Pharmacokinetics and serum albumin binding studies also suggest that compound 16 has the potential to be a candidate for the treatment of the nonhealing form of leishmaniasis.